Royal Wound-x News Press release Royal Biologics Announces Licensing and U.S. Commercial Launch of Bio-Reign 3D (TM) August 30, 2024 READ MORE Events Foundation NY20 for Podiatric Medicine August 30, 2024 READ MORE Press release Royal Biologics Announces Licensing and U.S. Commercial Launch of Bio-Reign 3D (TM) August 30, 2024 READ MORE Royal Wound-X Receives IRB Approval and Commences Randomized Controlled Trials for Pivotal Products September 11, 2024 Royal Biologics Announces Licensing and U.S. Commercial Launch of Bio-Reign 3D (TM)May 23, 2023 Royal Biologics Announces U.S. Commercial Launch of BIOINCYTE™ PRFMMay 14, 2023 Royal Biologics Announces U.S. Commercial Launch of Advanced-Cell™, an Advanced Bone Grafting and Fusion Convenience KitApril 26, 2022 Royal Biologics Announces Partnership With Vilex Launching Its ALC Technology Into Lower Extremity IndustryAugust 17, 2021 Royal Biologics Wound Care Portfolio Receives High-Tier ReimbursementFebruary 15, 2021 Royal Biologics Announces the Launch of Fibri-Cell™, Live Cellular Cortical Fibers With Osteo-Spin™ TechnologyNovember 10, 2020 Royal Biologics Completes 100th Cyro Cord™ Case, Successfully Enrolls First Patient Into Diabetic Foot Ulcer StudySeptember 29, 2020 Royal Biologics Announces the Acquisition of FIBRINETSeptember 1, 2020 Royal Biologics Announces the Launch of Cryo-Cord™, the First Non-DMSO Viable Umbilical Cord GraftJanuary 21, 2020 Royal Biologics announces the launch of MAGNUS, a DMSO-free viable cellular bone allograftJanuary 8, 2020 Granite Creek Capital Partners, L.L.C. Announces an Investment in Royal BiologicsJanuary 19, 2019 Royal Biologics Launches Maxx-Cell, the World’s Most Advanced Bone Marrow Aspiration DeviceDecember 12, 2018 Royal Biologics Launches MAXX™-Fuse Royal Biologics Launches Amnio-Maxx™, an Extracellular Matrix Product Derived From Human Amniotic Placental Tissue
